Vontobel Holding Ltd. grew its stake in shares of DaVita Inc. (NYSE:DVA – Free Report) by 17.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,243 shares of the company’s stock after acquiring an additional 329 shares during the quarter. Vontobel Holding Ltd.’s holdings in DaVita were worth $368,000 as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of the business. Global Assets Advisory LLC purchased a new position in DaVita in the 1st quarter worth approximately $2,360,000. Gateway Investment Advisers LLC purchased a new stake in shares of DaVita during the 1st quarter worth $218,000. Atlas Capital Advisors LLC lifted its stake in shares of DaVita by 137.0% during the 1st quarter. Atlas Capital Advisors LLC now owns 6,254 shares of the company’s stock worth $863,000 after purchasing an additional 3,615 shares during the last quarter. Fox Hill Wealth Management lifted its stake in shares of DaVita by 138.4% during the 1st quarter. Fox Hill Wealth Management now owns 15,734 shares of the company’s stock worth $2,172,000 after purchasing an additional 9,135 shares during the last quarter. Finally, Dumont & Blake Investment Advisors LLC lifted its stake in shares of DaVita by 2.1% during the 1st quarter. Dumont & Blake Investment Advisors LLC now owns 8,290 shares of the company’s stock worth $1,144,000 after purchasing an additional 170 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors.
DaVita Stock Performance
Shares of NYSE:DVA opened at $163.16 on Wednesday. The company has a debt-to-equity ratio of 9.94, a current ratio of 1.16 and a quick ratio of 1.12. The business’s 50 day moving average price is $157.10 and its 200-day moving average price is $144.89. The firm has a market capitalization of $14.31 billion, a PE ratio of 18.54, a P/E/G ratio of 0.93 and a beta of 0.87. DaVita Inc. has a 1 year low of $75.47 and a 1 year high of $168.50.
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on DVA shares. Bank of America increased their price target on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. UBS Group increased their price objective on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 8th. TD Cowen lifted their price target on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Finally, Truist Financial lifted their price target on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $159.00.
Read Our Latest Stock Report on DVA
Insiders Place Their Bets
In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the business’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the transaction, the insider now owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the transaction, the insider now owns 83,011 shares of the company’s stock, valued at $12,137,038.31. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Michael David Staffieri sold 9,539 shares of the company’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $150.03, for a total value of $1,431,136.17. Following the completion of the transaction, the chief operating officer now directly owns 241,945 shares in the company, valued at approximately $36,299,008.35. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 173,482 shares of company stock valued at $27,387,069. Insiders own 2.00% of the company’s stock.
About DaVita
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading
- Five stocks we like better than DaVita
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- 3 Warren Buffett Stocks to Buy Now
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Free Report).
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.